Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Illumina, Inc.    ILMN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Illumina : Patent Issued for Method for Nucleotide Detection (USPTO 9115353)

09/02/2015 | 05:38pm US/Eastern

By a News Reporter-Staff News Editor at Biotech Business Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Klausing, Kay (San Diego, CA); Smith, Vincent (Essex, GB); Shen, Min-Jui Richard (Poway, CA); Moore, John (San Diego, CA); Hall, Kevin (Essex, GB), filed on January 31, 2011, was published online on August 25, 2015 (see also Biotechnology Companies).

The assignee for this patent, patent number 9115353, is Illumina, Inc. (San Diego, CA).

Reporters obtained the following quote from the background information supplied by the inventors: "Numerous methods used to detect and characterize nucleic acid structures employ tagging schemes that rely on electromagnetic radiation (EM) emission of an excited state light-absorbing chromophore. Examples of such photoluminescent processes include phosphorescence and fluorescence emission. Fluorescence detection, for example, has been used in DNA sequencing to great effect due, in part, to the high degree of sensitivity allowing single molecule detection.

"Performing iterative fluorescent detection steps in an array context, such as sequencing by synthesis, can cause fluorescence signal intensity loss (see, for example, Fedurco et al. WO2006/064199). This problem was addressed, in part, by the addition of ascorbate to a detection solution to increase the number of useful detection cycles from about eight to ten cycles, in the absence of ascorbate, to about 25 cycles in the presence of ascorbate. The possible mechanisms that underlie this signal loss are numerous, and can include cleavage of individual nucleic acid members from the support.

"There are a number of pathways by which nucleic acid damage can occur during irradiation in fluorescence detection. Fluorescence emission normally occurs with the emission of light of a longer wavelength (lower energy), than the original irradiating source. However, under conditions in which intense EM radiation is being absorbed by the fluorophore, such as in laser-induced fluorescence (LIF), it is possible for a molecule to absorb two photons, which can lead to the emission of higher energy radiation of smaller wavelengths than the original excitation source. This multiple photon absorption can cause the fluorophore to emit EM radiation in the UV-visible region which can contribute to nucleic acid base dimerization and/or the generation of reactive oxygen species.

"For example, it has been indicated that exposure of whole cells to ultraviolet (UV) radiation can cause DNA damage via the direct photochemical [2+2] photocycloaddition reaction of thymine or cytosine to provide cyclobutane pyrimidine dimers, such as TT, TC, and CC. Such direct photocycloaddition reactions can occur in the UV B and UV C regions which extend from about 100 nm to about 315 nm.

"In the UV A region through a portion of the visible region, spanning from about 315 nm to about 500 nm, a complex mixture of indirect mechanisms can also cause DNA damage through photosensitization of other cellular components. Such indirect mechanisms can result in pyrimidine dimer formation and oxidative DNA modification via reactive species such as singlet oxygen, superoxide anion, and iron-promoted hydroxyl radical formation. Finally, it also has also been indicated that reactive singlet oxygen can be generated by fluorescence quenching of an excited state fluorophore by triplet oxygen. Any combination of direct or indirect pyrimidine dimerization and nucleic acid damage due to various reactive oxygen species observed in whole cells can be the underlying cause of fluorescence signal intensity loss observed in the array context.

"There is a need to further reduce fluorescent signal intensity loss for applications in sequencing by synthesis to facilitate sequencing of long nucleotide sequences, including sequences of 50, 75, 100, 200, and 500 nucleotides or more. Moreover, solutions to fluorescent signal intensity loss in the context sequencing by synthesis are readily applicable to other nucleic acid detection platforms that employ multiple irradiation steps. The present invention satisfies this need and provides related advantages as well."

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "Provided herein is a method of inhibiting light-induced degradation of nucleic acids. The method includes irradiating a portion of said nucleic acids in the presence of a detection solution comprising a polyphenolic compound. Also provided is a method of detecting a nucleic acid having a fluorescent tag. The method includes irradiating at least a portion of said nucleic acid with light, wherein said light comprises a suitable wavelength to induce a fluorescence emission, detecting the fluorescence emission. Optionally, the polyphenolic compound is gallic acid, a lower alkyl ester thereof, or mixtures thereof.

"In addition, provided herein is a kit comprising one or more nucleotides, an enzyme capable of catalyzing incorporation of the nucleotides into a nucleic acid strand and a polyphenolic compound suitable for preparing a detection solution."

For more information, see this patent: Klausing, Kay; Smith, Vincent; Shen, Min-Jui Richard; Moore, John; Hall, Kevin. Method for Nucleotide Detection. U.S. Patent Number 9115353, filed January 31, 2011, and published online on August 25, 2015. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9115353.PN.&OS=PN/9115353RS=PN/9115353

Keywords for this news article include: Chalcogens, Illumina Inc, Biotechnology Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC

(c) 2015 NewsRx LLC, source Health Newsletters

React to this article
Latest news on ILLUMINA, INC.
09/02 ILLUMINA : Patent Issued for Method for Nucleotide Detection (USPTO 9115353)
09/01 ILLUMINA : Completes Acquisition of GenoLogics
08/25 ILLUMINA : Burning Rock Biotech Enters into Agreement with Illumina
08/24 ILLUMINA : Burning Rock and Illumina Collaborate on Molecular Diagnostics for On..
08/19 ILLUMINA : Combine Solicitation - Illumina MiSeq One Year Service Contract
08/19 ILLUMINA : Combine Solicitation - Reagents for Illumina MiSeq Instrument
08/19 ILLUMINA : $287,967 Federal Contract Awarded to Illumina
08/19 ILLUMINA : NIH Plans Sole Source With Illumina for Maintenance Services
08/18 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina NeoPrep Librar..
08/18 ILLUMINA : Warburg Pincus, and Sutter Hill Ventures Form Helix to Accelerate Con..
Advertisement
Chart
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Income Statement Evolution
More Financials